Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) CFO David D. O’toole sold 432 shares of the business’s stock in a transaction that occurred on Monday, January 10th. The stock was sold at an average price of $30.60, for a total value of $13,219.20. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
Shares of Opiant Pharmaceuticals stock opened at $27.07 on Friday. The company has a debt-to-equity ratio of 0.45, a current ratio of 9.23 and a quick ratio of 9.23. Opiant Pharmaceuticals, Inc. has a 1 year low of $8.51 and a 1 year high of $37.71. The company has a market capitalization of $127.77 million, a P/E ratio of 541.51 and a beta of 0.51. The business has a 50 day moving average price of $30.12 and a 200 day moving average price of $23.26.
Opiant Pharmaceuticals (NASDAQ:OPNT) last issued its quarterly earnings data on Thursday, November 11th. The technology company reported $0.56 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.15 by $0.41. Opiant Pharmaceuticals had a return on equity of 4.25% and a net margin of 3.58%. The firm had revenue of $16.34 million during the quarter, compared to the consensus estimate of $12.45 million. During the same period in the previous year, the firm posted $0.15 EPS. As a group, research analysts expect that Opiant Pharmaceuticals, Inc. will post 0.39 EPS for the current fiscal year.
Institutional investors have recently modified their holdings of the stock. Two Sigma Investments LP acquired a new position in shares of Opiant Pharmaceuticals during the 3rd quarter worth approximately $1,314,000. Two Sigma Advisers LP acquired a new position in shares of Opiant Pharmaceuticals during the 3rd quarter worth approximately $2,139,000. BlackRock Inc. raised its position in shares of Opiant Pharmaceuticals by 107.2% during the 3rd quarter. BlackRock Inc. now owns 24,686 shares of the technology company’s stock worth $635,000 after purchasing an additional 12,774 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Opiant Pharmaceuticals by 7.5% during the 3rd quarter. Renaissance Technologies LLC now owns 205,615 shares of the technology company’s stock worth $5,293,000 after purchasing an additional 14,300 shares during the last quarter. Finally, Advisor Group Holdings Inc. raised its position in shares of Opiant Pharmaceuticals by 102.4% during the 3rd quarter. Advisor Group Holdings Inc. now owns 6,325 shares of the technology company’s stock worth $163,000 after purchasing an additional 3,200 shares during the last quarter. Hedge funds and other institutional investors own 26.90% of the company’s stock.
Opiant Pharmaceuticals Company Profile
Opiant Pharmaceuticals, Inc is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa.
Recommended Story: What is cost of equity?
Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.